- Conditions
- Obstructive Sleep Apnea, Hypertension
- Interventions
- AD113, Atomoxetine
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Towson, Maryland • Cincinnati, Ohio • Columbia, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obstructive Sleep Apnea, Down Syndrome
- Interventions
- Atomoxetine and oxybutynin (ato-oxy)
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Neurogenic Orthostatic Hypotension
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine and OROS Methylphenidate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- ABT-089, atomoxetine, placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • El Centro, California • Boulder, Colorado + 17 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine Hydrochloride, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 20
- States / cities
- Irvine, California • Gainesville, Florida • Tampa, Florida + 17 more
- Conditions
- Depressive Disorder, Parkinson Disease
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 30 Years to 79 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cocaine Dependence, Nicotine Dependence
- Interventions
- Progesterone, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Autism, Pervasive Development Disorder, Asperger's Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- atomoxetine, Placebo, Parent Management Training
- Drug · Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 3
- States / cities
- Rochester, New York • Columbus, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- atomoxetine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 1,553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • El Centro, California + 67 more
- Conditions
- Autism
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 5 Years to 15 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Lexington, Massachusetts
- Conditions
- Memory Disorders, Multiple Sclerosis
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Substance Use Disorders, Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Substance Abuse
- Interventions
- atomoxetine, placebo
- Drug
- Lead sponsor
- Sharon Walsh
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 17,418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Posttraumatic Stress Disorder With Attention Defic
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Menopause, Cognitive Disturbances
- Interventions
- atomoxetine, placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Parkinson's Disease, Freezing of Gait
- Interventions
- ATM FOG in PD
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Parkinson's Disease, Idiopathic
- Interventions
- Methylphenidate, Physical Therapy, Atomoxetine
- Drug · Other
- Lead sponsor
- Hubert Fernandez
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine Hydrochloride, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Atomoxetine, Oxybutynin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Tachycardia, Chronic Orthostatic Intolerance
- Interventions
- Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
- Drug · Other · Dietary Supplement + 3 more
- Lead sponsor
- Satish R. Raj
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- OSA
- Interventions
- Aroxybutynin and Atomoxetine
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Chandler, Arizona + 80 more
- Conditions
- Fetal Alcohol Syndrome, Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
- Interventions
- Strattera, Placebo
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma